Section 603 of the PACT Act Mandates Toxic Exposure Screening, But Current VA Screening Tools Exclude an Assessment of Mefloquine Neurotoxicity
The Neurotoxic Army-Developed Antimalarial Drug is Structurally Related to Hydroxychloroquine and Chloroquine and Carries a Risk of Potentially Severe Neuropsychiatric Adverse Effects
The Foundation has Written to Newly Confirmed Secretary of Health and Human Services, Xavier Becerra, Encouraging Liberal Consideration of Claims under the Countermeasures Injury Compensation Program
The National Academies of Sciences, Engineering and Medicine Finds Research is Needed into the Chronic Adverse Effects of Mefloquine and Related Quinoline Antimalarial Drugs
Services Will Aid U.S. Veterans Seeking VA Disability Benefits From the Neurotoxic Effects of Mefloquine and Related Quinoline Drugs
The Neurotoxic Army-Developed Antimalarial Drug is Structurally Related to Hydroxychloroquine and Chloroquine and Carries a Risk of Potentially Severe Neuropsychiatric Adverse Effects
Limiting Restrictions to Hydroxychloroquine Only Risks Substitution of More Dangerous Quinolines for Off-Label Self-Treatment and Prophylaxis of Disease
Use of Chloroquine, Hydroxychloroquine, Mefloquine, Quinine, and Related Quinoline Drugs Risks Sudden and Lasting Neuropsychiatric Effects from Idiosyncratic Neurotoxicity
The National Academies of Sciences, Engineering, and Medicine Finds Research is Needed into the Chronic Adverse Effects of Mefloquine and Related Quinoline Antimalarial Drugs
Despite Published CDC Recommendations, Krintafel® is Not Indicated by the FDA for Use in Presumptive Anti-Relapse Therapy
The Release Contains Statements Which Potentially Pose a Direct Threat to the Traveling Public’s Health by Undermining Important Warnings Recently Mandated by Drug Regulators to Reduce the Risk of Serious Disabling and Potentially Life-Threatening Adverse Effects From the Drug
The Foundation Supports Education and Research on Chronic Quinoline Encephalopathy, a Medical Condition That Can Mimic PTSD
Several Veterans Will Travel to Washington, DC to Attend the Second Meeting of the Committee to Tell Committee Members Their Case Reports of Long-Term Effects Went Unpublished by the U.S. Military and the Centers for Disease Control and Prevention
The Foundation Cautions the Department of Veterans Affairs (VA) Against Delaying Long-Overdue Action to Screen Veterans for Mefloquine Exposure Pending the Completion of the 18-Month Study
Recent Media Reports Have Highlighted the Plight of Peace Corps Volunteers Left Permanently Disabled from the Antimalarial Drug
Although DSM-5 Diagnostic Criteria Exclude the Diagnosis of PTSD if Symptoms Such as Insomnia and Nightmares Are Attributable to Medication Effects, VA Disability Examiners Do Not Routinely Screen Veterans for a History of Symptomatic Mefloquine Exposure
Mefloquine, a Component of TNH201, May Cause Neuropsychiatric Adverse Effects Including Cognitive Dysfunction and Nightmares That May Last Years After Use
Health Canada Warns that the Antimalarial Drug, Widely Prescribed to Members of the Canadian Armed Forces Since the Early 1990s, Can Cause Several Potentially Permanent and Disabling Conditions
The Foundation Announces a Pilot Program to License the Two-Question White River Mefloquine Instrument (WRMI-2) to Assist in Identifying Canadian Veterans with Disability from Dizziness, Balance Issues, and Other Conditions Potentially Caused by Mefloquine Exposure
Use of Tafenoquine During Military Deployments Could Lead to Adverse Effects Including Insomnia, Nightmares, and Anxiety Being Misattributed to the Sleep-Disrupting Effects of Travel or to the Effects of Trauma and Other Stressors.
The Foundation Warns that Psychiatric Symptoms Including Insomnia, Abnormal Dreams, and Nightmares Should be Considered Prodromal to More Serious Adverse Effects.
Use of the Two-Question White River Mefloquine Instrument (WRMI-2) Will Permit the National Centre for Trauma to Identify Veterans at Risk of Mefloquine Poisoning.
The Foundation has Shared Its Concerns for the Safety of the Newly-Approved Drug with the Bill & Melinda Gates Foundation and Medicines for Malaria Venture
The Foundation has Shared with GSK its Report Submitted to FDA in Advance of the July 12, 2018 Meeting of the Antimicrobial Drugs Advisory Committee at Which New Drug Application (NDA) 210795 Will be Considered
Veterans and VA Health Care Providers Must Be Provided With Up-To-Date Information That Accurately Reflects the Health Risks Posed by the Neurotoxic Drug
The Antimalarial Drug Can Cause Chronic Neurologic and Psychiatric Effects Among Some Veterans, but the Government Does Not Know How Many Veterans Were Exposed, and Which Veterans Are Suffering Symptoms of Poisoning from their Exposure
The Foundation Supports Education and Research on Chronic Quinoline Encephalopathy, a Medical Condition That Can Mimic PTSD
The Investigative Report on Mefloquine Use in the Peace Corps Was Cancelled Only Days Before Its Scheduled Airing in November 2017
On the Quarter Century Anniversary of the Death of Shidane Arone, Mounting Evidence Exposes the Need to Investigate the Role of Mefloquine Poisoning in the Incident
The Foundation Supports the Quinoline Veterans and Families Association in its Submission Related to Poisoning by Mefloquine, Tafenoquine, and Primaquine
UK Drug Regulators Now Warn that Symptoms of Sleep Disturbance During Use of Mefloquine Require the Drug's Immediate Discontinuation
The Foundation Supports Education and Research on Chronic Quinoline Encephalopathy, a Medical Condition That Can Mimic PTSD
